Statements (46)
Predicate | Object |
---|---|
gptkbp:instanceOf |
neurodegenerative disease
|
gptkbp:affects |
elderly people
|
gptkbp:alsoKnownAs |
gptkb:DLB
Lewy body dementia |
gptkbp:averageSurvivalAfterDiagnosis |
5 to 8 years
|
gptkbp:causedBy |
abnormal accumulation of alpha-synuclein protein
|
gptkbp:characterizedBy |
gptkb:REM_sleep_behavior_disorder
fluctuating cognition parkinsonism visual hallucinations progressive cognitive decline |
gptkbp:diagnosedBy |
clinical assessment
neuroimaging neuropathology |
gptkbp:differentialDiagnosis |
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease_dementia frontotemporal dementia |
gptkbp:firstDescribed |
gptkb:Kenji_Kosaka
1976 |
https://www.w3.org/2000/01/rdf-schema#label |
Dementia with Lewy bodies
|
gptkbp:ICD-10_code |
G31.8
|
gptkbp:MeSH_ID |
gptkb:D000544
|
gptkbp:OMIM |
127750
|
gptkbp:pathology |
loss of dopaminergic neurons
Lewy bodies in the brain |
gptkbp:prevalence |
accounts for 10-15% of dementia cases
second most common type of degenerative dementia after Alzheimer's disease |
gptkbp:prognosis |
progressive and fatal
|
gptkbp:riskFactor |
age
family history male gender |
gptkbp:symptom |
gptkb:depression
gptkb:REM_sleep_behavior_disorder falls autonomic dysfunction parkinsonism visual hallucinations delusions cognitive fluctuations sensitivity to antipsychotics |
gptkbp:treatment |
gptkb:levodopa
physical therapy cholinesterase inhibitors antidepressants |
gptkbp:bfsParent |
gptkb:DLB
|
gptkbp:bfsLayer |
7
|